潜江永安药业股份有限公司 审计报告及财务报表 二〇二三年度 潜江永安药业股份有限公司 审计报告及财务报表 （2023 年 01 月 01 日至 2023 年 12 月 31 日止） | | 目录 | 页次 | | --- | --- | --- | | 一、 | 审计报告 | 1-6 | | 二、 | 财务报表 | | | | 合并资产负债表和母公司资产负债表 | 1-4 | | | 合并利润表和母公司利润表 | 5-6 | | | 合并现金流量表和母公司现金流量表 | 7-8 | | | 合并所有者权益变动表和母公司所有者权益变动表 | 9-12 | | | 财务报表附注 | 1-119 | 审计报告 信会师报字[2024]第 ZE10137 号 潜江永安药业股份有限公司全体股东： 一、 审计意见 我们审计了潜江永安药业股份有限公司（以下简称永安药业）财 务报表，包括 2023 年 12 月 31 日的合并及母公司资产负债表，2023 年度的合并及母公司利润表、合并及母公司现金流量表、合并及母公 司所有者权益变动表以及相关财务报表附注。 我们认为，后附的财务报表在所有重大方面按照企业会计准则的 规定编制，公 ...

潜江永安药业股份有限公司 内部控制评价报告 潜江永安药业股份有限公司 2023年度内部控制评价报告 潜江永安药业股份有限公司全体股东： 根据《企业内部控制基本规范》及其配套指引的规定和其他内部控制监管要求（以下简 称企业内部控制规范体系），结合潜江永安药业股份有限公司（以下简称公司或本公司）内 部控制制度和评价办法，在内部控制日常监督和专项监督的基础上，我们对公司2023年12 月31日（内部控制评价报告基准日）的内部控制有效性进行了评价。 一、重要声明 公司按照企业内部控制规范体系的规定，建立健全和有效实施内部控制，评价其有效性， 并如实披露内部控制评价报告是公司董事会的责任。监事会对董事会建立和实施内部控制进 行监督。经理层负责组织领导企业内部控制的日常运行。 公司董事会、监事会及董事、监事、高级管理人员保证本报告内容不存在任何虚假记载、 误导性陈述或重大遗漏，并对报告内容的真实性、准确性和完整性承担个别及连带法律责任。 公司内部控制的目标是合理保证经营管理合法合规、资产安全、财务报告及相关信息真 实完整，提高经营效率和效果，促进实现发展战略。由于内部控制存在的固有局限性，故仅 能为实现上述目标提供合理保 ...

一、审议通过《2023 年度董事会工作报告》的议案 表决结果：同意 6 票，反对 0 票，弃权 0 票。 《2023 年度董事会工作报告》具体内容见刊登于中国证监会指定信息披露 媒体巨潮资讯网 http://www.cninfo.com.cn《2023 年年度报告》中的"第三节 管 理层讨论与分析"、"第四节 公司治理"等章节的相关内容。 证券代码：002365 证券简称：永安药业 公告编号：2024-13 潜江永安药业股份有限公司 第六届董事会第二十次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 潜江永安药业股份有限公司（以下简称"公司"）第六届董事会第二十次会 议的会议通知于 2024 年 4 月 3 日以书面、电话、传真、电子邮件等形式送达公 司全体董事，会议于 2024 年 4 月 17 日在公司会议室以现场及通讯相结合的方式 召开，本次会议应出席董事 6 人，实际出席董事 6 人，公司部分监事及高管列席 了会议。本次会议的召集和召开符合《公司法》及《公司章程》的规定。会议以 书面记名投票方式逐项表决，通过了如下决议： 公司第六届独立董 ...

关于潜江永安药业股份有限公司 2023 年度营业收入扣除情况表的 鉴证报告 关于潜江永安药业股份有限公司2023年度 营业收入扣除情况表的鉴证报告 信会师报字[2024]第ZE10140号 潜江永安药业股份有限公司全体股东： 三、工作概述 我们按照《中国注册会计师其他鉴证业务准则第3101号——历史 财务信息审计或审阅以外的鉴证业务》的规定执行了鉴证业务。该准 则要求我们遵守职业道德规范，计划和实施鉴证工作，以对营业收入 扣除情况表是否在所有重大方面按照《深圳证券交易所股票上市规则》 鉴证报告第 1 页 和《深圳证券交易所上市公司自律监管指南第1号——业务办理》的 相关规定编制，如实反映永安药业2023年度营业收入扣除情况获取合 理保证。在执行鉴证工作过程中，我们实施了包括询问、检查会计记 录等我们认为必要的程序。我们相信，我们的鉴证工作为发表鉴证结 论提供了合理的基础。 我们审计了潜江永安药业股份有限公司(以下简称"永安药 业")2023 年度的财务报表，包括 2023 年 12 月 31 日的合并及母公司 资产负债表、2023 年度合并及母公司利润表、合并及母公司现金流 量表、合并及母公司所有者权益变动表 ...

潜江永安药业股份有限公司 独立董事 2023 年度述职报告 各位股东及股东代表： 本人作为潜江永安药业股份有限公司（以下简称"公司"）的独立董事，严 格遵守《公司法》《证券法》《上市公司独立董事管理办法》《深圳证券交易所 上市公司自律监管指引第 1 号—主板上市公司规范运作》等相关法律法规以及 《公司章程》《独立董事工作制度》等相关规定，在 2023 年的工作中，本着诚 信、勤勉、尽责的态度，认真行权，依法履职，积极出席公司会议，认真审议各 项议案，充分发挥了独立董事的独立性和专业性，切实维护了公司和全体股东尤 其是中小股东的合法权益，现将本人在 2023 年度履职情况报告如下： 一、基本情况 （一）工作履历 本人赵纯祥，1978 年生，中国国籍，无境外永久居留权，教授，中南财经 政法大学财务管理系副主任，会计学博士，中国成本研究会第七届理事会理事， 中国经济与会计监管研究中心主任，中国注册会计师（非执业会员），澳大利亚 Curtin 大学、中国台湾政治大学访问学者。主要研究管理者激励、成本管理、 宏观经济政策与企业财务行为等问题，主持或主研《转型经济背景下我国企业员 工收入差距研究》、《湖北省国有企业创新导 ...

（一）独立聘请中介机构，对公司具体事项进行审计、咨询或者核查； 潜江永安药业股份有限公司 独立董事专门会议工作细则 第一章 总 则 第一条 为进一步完善潜江永安药业股份有限公司（以下简称"公司"）法 人治理结构，规范独立董事专门会议的运作，保障独立董事有效履职，根据《中 华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》、 《上市公司独立董事管理办法》、《深圳证券交易所上市公司自律监管指引第 1 号—主板上市公司规范运作》等有关法律、法规、规范性文件以及《公司章程》 的有关规定，结合公司实际情况，制定本细则。 第二条 独立董事专门会议是指全部由公司独立董事参加的会议。 第二章 职责权限 第三条 下列事项应当经独立董事专门会议审议： （四）应当披露的关联交易； （五）公司及相关方变更或者豁免承诺的方案； （六）被收购公司董事会针对收购所作出的决策及采取的措施； （七）法律、行政法规、中国证监会规定和公司章程规定的其他事项。 本条第一项至第三项所列事项为独立董事行使特别职权所需的必要审议程 序，应当由独立董事专门会议审议后经全体独立董事过半数同意。 本条第四项至第七项所列事项为董事会特定议案 ...

潜江永安药业股份有限公司 独立董事 2023 年度述职报告 各位股东及股东代表： 本人作为潜江永安药业股份有限公司（以下简称"公司"）的独立董事，严 格遵守《公司法》《证券法》《上市公司独立董事管理办法》《深圳证券交易所 上市公司自律监管指引第 1 号—主板上市公司规范运作》等相关法律法规以及 《公司章程》《独立董事工作制度》等相关规定，在 2023 年的工作中，本着诚 信、勤勉、尽责的态度，认真行权，依法履职，积极出席公司会议，认真审议各 项议案，充分发挥了独立董事的独立性和专业性，切实维护了公司和全体股东尤 其是中小股东的合法权益，现将本人在 2023 年度履职情况报告如下： 一、基本情况 （一）工作履历 2023 年，公司共召开董事会会议 6 次，股东大会会议 1 次，本人出席会议 的具体情况如下： | 独立董事 | 本年度应 | 以现场方式 | 以通讯表决 | 委托出 | 缺席 | 是否连续 | 出席股东 | | --- | --- | --- | --- | --- | --- | --- | --- | | 姓名 | 参加董事 | 参加董事会 | 方式参加董 | 席次数 | 次数 | 两次未出 | ...

潜江永安药业股份有限公司 2023 年度 非经营性资金占用及其他关联资金往来情况汇总表 单位：万元 | | | 占用方与上市公司的 | 上市公司核算的会计 | 2023 年期初 | 2023 年度占用 | 2023 年度占用 | 2023 年度偿 | 2023 年期末 | 占用 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 非经营性资金占用 | 资金占用方名称 | 关联关系 | 科目 | 占用资金余 | 累计发生金额 | 资金的利息 | 还累计发生 | 占用资金余 | 形成 | 占用性质 | | | | | | 额 | （不含利息） | (如有) | 金额 | 额 | 原因 | | | 控股股东、实际控制人及其 | | | | | | | | | | 非经营性占用 | | 附属企业 | | | | | | | | | | 非经营性占用 | | 小计 | - | - | - | | | | | | - | - | | 前控股股东、实际控制人及 | | | | | | | | | | 非经营性占用 | | 其附属 ...

Share Capital and Dividends - The company's total share capital is 294,682,500 shares, with no changes during the reporting period[16] - The company plans to distribute a cash dividend of 1 yuan per 10 shares (tax included) based on a total of 294,682,500 shares[4] Senior Management Changes - The company's senior management changes in 2023 included the appointment of Chen Zidi and Guo Dianhai, and the resignation of Dai Xiangzhen, Wu Xiaobo, and Mei Songlin[17] Restricted Shares - The company's restricted shares increased by 163,013 shares and decreased by 115,513 shares during the reporting period, resulting in a total of 536,537 restricted shares at the end of the period[21] Shareholder Structure - The total number of ordinary shareholders at the end of the reporting period is 28,260[22] - The largest shareholder, Chen Yong, holds 21.54% of the shares, totaling 63,468,000 shares[22] - Huanggang Yong'an Pharmaceutical Co., Ltd. holds 3.57% of the shares, totaling 10,529,232 shares[22] - Central Huijin Asset Management holds 2.58% of the shares, totaling 7,610,350 shares[22] - The top 10 shareholders include 5 individuals and 5 corporate entities, with no significant changes in shareholding percentages during the reporting period[22][27] - The company's controlling shareholder is Chen Yong, a natural person with no changes in control during the reporting period[31] - The top 10 shareholders did not engage in any repurchase agreements during the reporting period[30] - The company's actual controller is a natural person, with no changes in control during the reporting period[32] - The company's shares are primarily held in RMB ordinary shares, with no significant changes in share structure[27] - The company's shareholder structure remains stable, with no significant changes in the top 10 shareholders' positions[22][27] Financial Performance - Revenue for 2023 decreased by 33.48% to RMB 972,890,144.84 compared to 2022[50] - Net profit attributable to shareholders in 2023 was a loss of RMB -12,312,563.51, a decrease of 108.77% from 2022[50] - Operating cash flow decreased by 42.88% to RMB 221,196,161.28 in 2023[50] - Basic earnings per share in 2023 were RMB -0.0418, a decrease of 108.78% from 2022[50] - Total assets at the end of 2023 decreased by 3.18% to RMB 2,347,138,093.66 compared to 2022[50] - Shareholders' equity at the end of 2023 decreased by 1.66% to RMB 1,983,913,143.72[50] - Weighted average return on equity in 2023 was -0.61%, a decrease of 7.84 percentage points from 2022[50] - Revenue from main business operations in 2023 was RMB 959,372,808.56 after deducting other business income[50] - Revenue for Q1 was 311.17 million yuan, Q2 was 267.27 million yuan, Q3 was 224.38 million yuan, and Q4 was 170.07 million yuan[56] - Net profit attributable to shareholders was 14.98 million yuan in Q1, 41.14 million yuan in Q2, -9.70 million yuan in Q3, and -58.74 million yuan in Q4[56] - Non-recurring gains and losses included 45.01 million yuan from the disposal of non-current assets and 10.84 million yuan from government subsidies[57] - Main business revenue for 2023 was 959.37 million yuan[81] - Total operating revenue for 2023 decreased to 972,890,144.84 yuan from 1,462,447,548.32 yuan in 2022, representing a 33.5% decline[164] - Net profit for 2023 was -28,414,556.08 yuan, a significant drop from 132,720,371.92 yuan in 2022[166] - Research and development expenses increased slightly to 41,500,983.96 yuan in 2023, up from 40,449,406.92 yuan in 2022[164] - Total liabilities decreased to 176,373,184.19 yuan in 2023 from 161,294,174.51 yuan in 2022[164] - Total owner's equity decreased to 2,005,830,451.82 yuan in 2023 from 2,057,638,701.11 yuan in 2022[164] - Basic earnings per share (EPS) for 2023 was -0.0418 yuan, compared to 0.4762 yuan in 2022[168] - Total comprehensive income for 2023 was -27,519,802.76 yuan, down from 137,788,341.31 yuan in 2022[168] - Parent company's operating income for 2023 was 740,881,026.05 yuan, a decrease from 1,010,850,278.63 yuan in 2022[170] - Parent company's net profit for 2023 was -28,414,556.08 yuan, compared to 132,720,371.92 yuan in 2022[170] - Parent company's research and development expenses for 2023 were 30,710,085.61 yuan, slightly down from 32,377,811.14 yuan in 2022[170] - Net profit for the year was -28,242,019.04, a significant decline compared to the previous year's profit of 140,353,899.08[173] - Operating cash flow decreased to 221,196,161.28 from 387,279,801.68 in the previous year[177] - Cash received from sales of goods and services dropped to 994,883,578.48 from 1,554,482,672.91 year-over-year[174] - Total cash inflow from operating activities decreased to 1,048,978,861.76 from 1,699,802,771.05[177] - Cash outflow for operating activities reduced to 827,782,700.48 from 1,312,522,969.37[177] - Investment cash inflow increased to 1,461,952,825.25 from 1,029,366,408.96[177] - Investment cash outflow rose to 1,604,940,968.87 from 1,259,761,476.79[177] - Net cash flow from investment activities improved to -142,988,143.62 from -230,395,067.83[177] - Cash and cash equivalents at year-end stood at 294,228,203.22, up from 274,714,697.91[180] - The company's cash position increased by 19,513,505.31 during the year[180] - Operating cash flow decreased to 165.3 million yuan in 2023 from 328.8 million yuan in 2022, a decline of 49.7%[181] - Sales revenue from goods and services dropped to 707.2 million yuan in 2023 from 1.1 billion yuan in 2022, a decrease of 36%[181] - Investment cash outflow increased to 1.25 billion yuan in 2023 from 1.15 billion yuan in 2022, up 9.1%[181] - Net cash flow from investment activities improved to -149.4 million yuan in 2023 from -224.1 million yuan in 2022[181] - Total owner's equity decreased by 54.7 million yuan in 2023, with a -33.5 million yuan reduction in parent company equity[183] - Comprehensive income for 2023 showed a loss of 41.8 million yuan in undistributed profits[183] - Dividend distribution in 2023 totaled 29.5 million yuan, with an additional 6 million yuan allocated to minority shareholders[186] - Special reserves increased by 7.3 million yuan in 2023, with 9.7 million yuan extracted and 2.4 million yuan used during the year[190] - Total comprehensive income for the period increased by RMB 145,417,090.80, driven by a net profit of RMB 140,349,121.41[193] - Capital reserves increased by RMB 549,202.33 due to owner contributions and capital reductions[193] - Profit distribution included an extraction of surplus reserves amounting to RMB 14,035,389.91 and a distribution to owners of RMB 1,120,187.45[196] - Special reserves for the period amounted to RMB 5,491,125.47, with an extraction of RMB 10,991,548.41 and usage of RMB 5,500,422.94[199] - Total owner's equity at the beginning of the year was RMB 2,057,638,701.11, with a decrease of RMB 51,808,249.29 during the period[200] Business Diversification and Risks - The company faces risks including safety and environmental protection, operational, exchange rate, and management risks[4] - The company has diversified its business into areas such as hydrogen energy, health products, and chemical materials[48] - The company is actively seeking new products and projects to diversify its offerings and enhance risk resistance in the superplasticizer sector[89] Taurine Production and Market - The company's taurine production capacity is 58,000 tons per year, accounting for approximately 50% of the market share[63] - Taurine products are exported worldwide and are key suppliers to companies like Red Bull, Nestlé, and Coca-Cola[63] - Taurine demand is rapidly increasing in the beverage and health food sectors, especially in functional drinks and pet food, with significant growth in the domestic market[88] - The company is the largest taurine production base globally, with major production concentrated in China[88] - The new national standard for taurine in infant formula, implemented in February 2023, has increased the required taurine content, reflecting official recognition of its benefits[88] - Taurine production capacity is 58,000 tons/year with a utilization rate of 90.00%, and a new 40,000 tons/year capacity project is under construction with an investment of 250 million yuan[100] - The company is the largest taurine production base globally, holding approximately 50% of the market share[106] - The company is constructing a new 40,000 tons/year taurine production line, which will increase total capacity to nearly 100,000 tons/year[106] - The company obtained 11 new patents during the reporting period, including 2 Chinese invention patents related to taurine production[106] - Taurine production increased by 18.09% to 44,700 tons, with significant reductions in production costs, especially energy consumption[144] - Taurine sales grew by 10.97% to approximately 42,700 tons despite a price drop of over 30%[144] - Taurine production increased by 18.09% to 44,742.09 tons, while sales rose by 10.97% to 42,728.24 tons[153] Health Food and Supplements - The health food market is expanding due to aging population and rising health awareness, with increasing demand for nutritional supplements[92] - The company's subsidiary, Yongankangjian, focuses on developing a health industry chain centered around taurine, offering functional foods and dietary supplements[93] - Regulatory policies are becoming stricter, which is expected to improve the health food market environment and consumer confidence[93] - The health food industry is benefiting from favorable policies under the "Healthy China 2030" initiative, emphasizing prevention and early intervention[93] - Health supplement sales surged by 110.94% to 10,597,609 bottles, with production up by 113.65% to 10,661,652 bottles[155] Chemical Manufacturing and Superplasticizers - The polycarboxylate superplasticizer industry is in a mature phase, with demand weakened due to economic slowdown and reduced construction activities[89] - The company's subsidiary, Ling'an Technology, is working to reduce production costs and improve product quality in the superplasticizer sector[89] - Polycarboxylate-based water reducer production capacity is 144,000 tons/year for polyether and 70,000 tons/year for water reducer, with a utilization rate of 10.46%[100] Procurement and Costs - Epoxyethane procurement accounted for 30.67% of total procurement, with an average price of 6,794.22 in the first half of the year and 6,373.97 in the second half[95] - Energy procurement costs accounted for over 30% of total production costs[96] - Raw material costs for pharmaceutical manufacturing accounted for 41.34% of total operating costs, a slight increase of 0.24% year-over-year[156] Assets and Liabilities - Total current assets increased to 1,213,596,306.81 yuan in 2023 from 1,195,344,274.49 yuan in 2022[125] - Monetary funds grew to 326,171,803.22 yuan in 2023 compared to 274,716,138.81 yuan in 2022[125] - Trading financial assets rose to 630,099,163.70 yuan in 2023 from 557,503,180.92 yuan in 2022[125] - Accounts receivable decreased to 165,473,255.39 yuan in 2023 from 172,942,083.99 yuan in 2022[125] - Inventory dropped significantly to 69,895,984.49 yuan in 2023 from 149,597,978.67 yuan in 2022[125] - Fixed assets declined to 927,635,265.65 yuan in 2023 from 971,902,018.29 yuan in 2022[125] - Long-term equity investment decreased to 68,300,352.29 yuan in 2023 from 81,374,014.12 yuan in 2022[125] - Construction in progress reduced to 26,118,014.36 yuan in 2023 from 51,548,767.55 yuan in 2022[125] - Intangible assets slightly decreased to 82,393,203.12 yuan in 2023 from 84,493,498.07 yuan in 2022[125] - Goodwill significantly dropped to 517,416.38 yuan in 2023 from 8,766,208.59 yuan in 2022[125] - Total assets decreased from 2,424,179,175.81 to 2,347,138,093.66[128] - Non-current assets decreased from 1,228,834,901.32 to 1,133,541,786.85[128] - Current liabilities decreased from 285,127,152.95 to 257,255,645.43[128] - Fixed assets remained stable at 786,497,947.13 compared to 788,968,794.19[132] - Intangible assets decreased from 60,464,704.05 to 57,666,743.46[132] - Total liabilities decreased from 129,165,810.92 to 148,416,325.59[132] - Deferred tax assets increased from 5,613,717.73 to 7,568,578.39[132] - The company's total liabilities decreased to RMB 298.85 million from RMB 321.17 million[161] - Total equity decreased to RMB 2.05 billion from RMB 2.10 billion, with a decline in undistributed profits to RMB 812.69 million[161] Subsidiaries and Patents - Subsidiary Yong'an Kangjian developed over 220 new products in functional nutrition, health foods, and special dietary foods[142] - The company holds 28 patents, including 8 utility patents obtained during the reporting period[141] - The "Chu Niu" brand has gained high recognition and reputation both domestically and internationally[142] - The company has 46 patents related to taurine production and 27 utility model patents and 1 transferred invention patent related to polycarboxylate-based water reducers[97][100] Revenue Breakdown - Total revenue decreased by 33.48% to 972.89 million yuan, with the pharmaceutical manufacturing sector contributing 68.06% of total revenue[149] - Revenue from the chemical manufacturing sector dropped by 41.57% to 121.47 million yuan, accounting for 12.49% of total revenue[149] - Revenue from health food products declined by 49.94% to 156.77 million yuan, making up 16.11% of total revenue[149] - International sales accounted for 58.36% of total revenue, decreasing by 16.46% to 567.80 million yuan[149] - Domestic sales fell by 48.25% to 405.09 million yuan, representing 41.64% of total revenue[149] - Online sales plummeted by 70.73% to 77.31 million yuan, contributing 7.95% to total revenue[149] - Offline sales decreased by 25.26% to 895.58 million yuan, making up 92.05% of total revenue[149] - Pharmaceutical manufacturing revenue decreased by 25.03% to RMB 662.17 million, with a gross margin of 29.40%[152] - Chemical manufacturing revenue dropped by 41.57% to RMB 121.47 million, resulting in a negative gross margin of -10.70%[152] - Health supplement revenue fell by 49.94% to RMB 156.77 million, with a gross margin of 35.73%[152] - Overseas revenue accounted for 34.25% of total revenue, decreasing by 16.46% to RMB 567.80 million[152] - Online sales revenue plummeted by 70.73% to RMB 77.31 million, with a gross margin of 48.90%[152] Certifications and Quality - The company received a standard unqualified audit opinion from Ernst & Young for its 2023 financial statements[77] - The company achieved a BRCGS A+ certification for taurine production and maintained ISO 9001 and ISO 22000 certifications for its subsidiary Yong'an Kangjian[147] Shareholder Equity and Reserves - Total owner's equity at the beginning of the year was RMB 2,057,638,701.11, with a decrease

证券代码：002365 证券简称：永安药业 公告编号：2024-12 潜江永安药业股份有限公司 关于购买理财产品的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 潜江永安药业股份有限公司（以下简称"公司"）于 2023 年 5 月 23 日召开 第六届董事会第十六次会议，审议通过了《关于使用自有资金进行委托理财的议 案》，同意公司及子公司总计使用最高额度不超过（含）人民币 7 亿元的自有资 金进行委托理财。上述额度可滚动使用，有效期自董事会审议通过之日起不超过 12 个月，并授权公司管理层具体实施相关事宜。公司根据上述决议，择机购买 了相关理财产品，现将有关情况公告如下： 一、理财产品的主要情况 （一）2024 年 4 月 9 日，公司出资 3000 万元，向华泰证券股份有限公司（以 下简称"华泰证券"）购买理财产品，具体情况如下： 1、产品名称：平安信托周周成长债券投资集合资金信托计划 2、产品主要投资范围： 信托计划投资范围：利用受托人在金融领域的品牌和金融同业方面的资源， 将信托资金投资于货币市场工具及存款工具，银行间、交易所债券：交易所及银 ...